Protecting the World from Pertussis and Other Emerging Diseases
BioNet is a leading developer and manufacturer of vaccines, specializing in recombinant and mRNA-based solutions targeting respiratory diseases and other global public health challenges. With a proven track record in research, development, and biomanufacturing, BioNet has successfully advanced proprietary recombinant pertussis vaccines from early-stage innovation to licensure.
The European Commission Grants Marketing Authorisation for a First-of-its-Kind Pertussis-Only Vaccine for Vaccination of Teenagers, Adults and Pregnant Women in the European Union
Europeans in the European Union (EU) may soon have the choice to get vaccinated against whooping cough with a new pertussis-only vaccine that is about to hit the market.
On January 9, 2026, the EU Commission granted Marketing Authorisation to BioNet for its new acellular pertussis vaccine VacPertagen. This follows the favourable opinion issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) on November 13, 2025.
Clinical Evidence Supporting EU Authorisation
First Standalone Pertussis Vaccine Authorised in the European Union
EU-Authorised Pertussis Booster Vaccination for Teenagers
BioNet Achieves EU-GMP Certification for its Pertussis Vaccine Manufacturing
New Pertussis Vaccine Set for Implementation
The Committee for Medicinal Products for Human Use (CHMP), a part of the European Medicines Agency (EMA), recently recommended approval of a pertussis vaccine for teenagers, adults and newborns.
According to the agency, VacPertagen could serve as an effective pertussis booster vaccine for kids aged 12 and above, helping prevent diagnoses of whooping cough. It could also offer passive protection to infants when administered to pregnant women in their 2nd or 3rd trimesters.